When Prostate Cancer Circulates in the Bloodstream

Diagnostics

Virginie Vlaeminck-Guillem¹ 

[1] Cancer Research Centre of Lyon, U1052 INSERM, CNRS 5286, Léon Bérard Centre, Lyon I University, 28 rue Laennec, Lyon 69008, France

关键词: prostate cancer;    circulating biomarker;    diagnosis;    tumor aggressiveness;    metastasis;    circulating tumor cells;    extracellular vesicles;    exosomes;    free cell DNA;    miRNA;   

DOI  :  10.3390/diagnostics5040428

来源: mdpi

【 摘 要 】

Management of patients with prostate cancer is currently based on imperfect clinical, biological, radiological and pathological evaluation. Prostate cancer aggressiveness, including metastatic potential, remains difficult to accurately estimate. In an attempt to better adapt therapeutics to an individual (personalized medicine), reliable evaluation of the intrinsic molecular biology of the tumor is warranted, and particularly for all tumor sites (primary tumors and secondary sites) at any time of the disease progression. As a consequence of their natural tendency to grow (passive invasion) or as a consequence of an active blood vessel invasion by metastase-initiating cells, tumors shed various materials into the bloodstream. Major efforts have been recently made to develop powerful and accurate methods able to detect, quantify and/or analyze all these circulating tumor materials: circulating tumors cells, disseminating tumor cells, extracellular vesicles (including exosomes), nucleic acids, etc. The aim of this review is to summarize current knowledge about these circulating tumor materials and their applications in translational research.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.